文献速递肿瘤 PET/CT神经核医学

神经内分泌肿瘤患者中64Cu-DOTATATE PET:注射后1小时与3小时成像的前瞻性头对头比较

64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection.
PubMed 文献 · J Nucl Med · 2020-05-22

前瞻性研究对35例神经内分泌肿瘤(NEN)患者注射200 MBq 64Cu-DOTATATE后1小时与3小时行PET/CT头对头比较,计数病灶并经负二项回归分析。共发现822个一致病灶和5个不一致病灶(4个判定为真),1小时与3小时检出病灶数无显著差异;关键器官肿瘤/正常组织比值在1–3小时窗口内保持较高。结论认为成像时间窗可从1小时扩展至1–3小时而不显著影响病灶检出数。

要点

  • 35例NEN患者注射200 MBq 64Cu-DOTATATE后1小时与3小时PET/CT检出病灶数无显著差异。
  • 共822个一致病灶、5个不一致病灶,其中4个判定为真。
  • 1–3小时窗口内肝、肠、胰、骨肿瘤/正常组织比值保持较高。

核心结论

  • NEN患者64Cu-DOTATATE PET/CT成像时间窗可从注射后1小时扩展至1–3小时,病灶检出数无显著差异。

研究设计与样本

  • 前瞻性研究,对35例NEN患者注射200 MBq 64Cu-DOTATATE后1小时与3小时行PET/CT头对头比较。
  • 病灶按器官或区域分组计数,采用负二项回归比较;不一致病灶经同期CT或后续MR、CT或生长抑素受体显像证实为真。

主要发现

  • 共发现822个一致病灶(1小时与3小时均可见)和5个不一致病灶,其中4个判定为真。
  • 1例患者的不一致病灶位于淋巴结,仅3小时可见而1小时未见,因该患者另有11个一致肝病灶,未改变其疾病分期(IV期)。
  • 1小时与3小时检出病灶数无显著差异。
  • 肿瘤/正常组织比值:肝1小时12.6(95%CI 10.2–14.9)vs 3小时11.0(95%CI 8.7–13.4)。
  • 肿瘤/正常组织比值:肠1小时24.2(95%CI 14.9–33.4)vs 3小时28.2(95%CI 16.5–40.0);胰1小时42.4(95%CI 12.3–72.5)vs 3小时41.1(95%CI 8.7–73.4);骨1小时103.0(95%CI 38.6–167.4)vs 3小时124.2(95%CI 57.1–191.2)。

临床怎么用

  • 作者结论认为NEN患者64Cu-DOTATATE PET/CT成像时间窗可从1小时扩展至1–3小时,病灶检出数无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

64Cu-DOTATATE PET/CT imaging 1 h after injection is excellent for lesion detection in patients with neuroendocrine neoplasms (NENs). We hypothesized that the imaging time window can be extended up to 3 h after injection without significant differences in the number of lesions detected. Methods: From a prospective study, we compared, on a head-to-head basis, sets of 64Cu-DOTATATE PET/CT images from 35 patients with NENs scanned 1 and 3 h after injection of 200 MBq of 64Cu-DOTATATE. The number of lesions on both PET scans was counted and grouped according to organs or regions and compared with negative binomial regression. Discordant lesions (visible on only the 1-h images or only the 3-h 64Cu-DOTATATE PET images) were considered true if found on simultaneous CT or later MR, CT, or somatostatin receptor imaging. We measured lesion SUVmax, reference normal-organ or -tissue SUVmean, and tumor-to-normal-tissue ratios calculated from SUVmax and SUVmeanResults: We found 822 concordant lesions (visible on both 1-h and 3-h 64Cu-DOTATATE PET) and 5 discordant lesions, of which 4 were considered true. One discordant case in 1 patient involved a discordant organ system (lymph node) detected on 3-h but not 1-h 64Cu-DOTATATE PET that did not alter the patient's disease stage (stage IV) because the patient had 11 additional concordant liver lesions. We found no significant differences between the number of lesions detected on 1-h and 3-h 64Cu-DOTATATE PET. Throughout the 1- to 3-h imaging window, the mean tumor-to-normal-tissue ratio remained high in all key organs: liver (1 h: 12.6 [95% confidence interval (CI), 10.2-14.9]; 3 h: 11.0 [95%CI, 8.7-13.4]), intestines (1 h: 24.2 [95%CI, 14.9-33.4]; 3 h: 28.2 [95%CI, 16.5-40.0]), pancreas (1 h: 42.4 [95%CI, 12.3-72.5]; 3 h: 41.1 [95%CI, 8.7-73.4]), and bone (1 h: 103.0 [95%CI, 38.6-167.4]; 3 h: 124.2 [95%CI, 57.1-191.2]). Conclusion: The imaging time window of 64Cu-DOTATATE PET/CT for patients with NENs can be expanded from 1 h to 1-3 h without significant differences in the number of lesions detected.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Loft M, Carlsen EA, Johnbeck CB, et al. 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection. J Nucl Med. 2020. PMID: 32444370. doi:10.2967/jnumed.120.244509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。